edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: RTW Biotech Opportunities
Edison Investment Research is terminating coverage on RTW Biotech Opportunities (RTW). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
RTW Biotech Opportunities — 1 video in collection
Edison’s head of investment companies, Rob Murphy, met Roderick Wong, managing director of RTW Investments, to discuss RTW Biotech Opportunities (RTW Bio; ticker RTW/RTWG). Wong outlines RTW Bio’s outperformance versus its two biotech index benchmarks in 2023 and since the fund’s launch in October 2019. He also discusses his outlook for the biotech industry in 2024. Furthermore, Wong highlights RTW Bio’s acquisition of Arix Bioscience’s assets and the anticipated timeline for the deal to be completed. Finally, Wong reiterates his vision for RTW Bio and how it fits in with RTW Investments’ other funds.
Get access to the very latest content matched to your personal investment style.